Relation of Adiponectin to Glucose Tolerance Status, Adiposity, and Cardiovascular Risk Factor Load
Objective. Adiponectin has anti-atherogenic and anti-inflammatory properties. We investigated the influence of adiponectin on glucose tolerance status, adiposity and cardiovascular risk factors (CVRFs). Design and Patients. Study consisted of 107 subjects: 55 with normal glucose tolerance (NGT) and...
Gespeichert in:
| Veröffentlicht in: | Experimental diabetes research 2012-01, Vol.2012 (2012), p.1-5 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5 |
|---|---|
| container_issue | 2012 |
| container_start_page | 1 |
| container_title | Experimental diabetes research |
| container_volume | 2012 |
| creator | Boaz, M. Gavish, D. Matas, Z. Shargorodsky, M. Wolfson, N. |
| description | Objective. Adiponectin has anti-atherogenic and anti-inflammatory properties. We investigated the influence of adiponectin on glucose tolerance status, adiposity and cardiovascular risk factors (CVRFs). Design and Patients. Study consisted of 107 subjects: 55 with normal glucose tolerance (NGT) and 52 with impaired glucose regulation (IGR) who were divided into two groups: 24 subjects with impaired fasting glucose (IFG Group) and 28 patients with type 2 diabetes mellitus (DM Group). In additional analysis, study participants were divided into two groups, according to CVRFs: low and high risk. Measurements: Patients were evaluated for glucose, HbA1C, insulin, lipids, CRP, HOMA-IR and adiponectin. Measurements. Patients were evaluated for glucose, HbA1C, insulin, lipids, CRP, HOMA-IR and adiponectin. Results. Adiponectin was significantly higher in NGT group than in IFG (P=0.003) and DM (P=0.01) groups. Adiponectin was significantly, positively associated with HDL and inversely associated with glucose, HbA1c, ALT, AST, TG, HOMA-IR. Patients with higher CVRFs load have lesser adiponectin compared to patients with low cardiovascular risk P |
| doi_str_mv | 10.1155/2012/250621 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3255106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>916853059</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-3fb510c13994528f388427a4927fdde5bd7984e8dec56dae7fa0e15f821b51833</originalsourceid><addsrcrecordid>eNqFkctPVTEQxk-MRhBcudZ0R6Jc6fM8NibkBtDkJiaA62ZuO5Xque217YHw31Ny4EZXrmaS-c03j69p3jH6mTGlTjhl_IQr2nL2otlnbd8tlKDi5XPOmdxr3uT8i1LZKtW_bvY450q0TO435hJHKD4GEh05tX4bA5riAymRXIyTiRnJdRwxQTBIrgqUKR_PYPbl_phAsGQJyfp4C9lMIyRy6fNvcg6mxERWEexh88rBmPHtUzxofpyfXS-_LlbfL74tT1cLI0VXFsKtFaOGiWGQivdO9L3kHciBd85aVGvbDb3E3qJRrQXsHFBkyvWc1cZeiIPmy6y7ndYbtAZDSTDqbfIbSPc6gtf_VoK_0T_jrRZc1cltFTh6Ekjxz4S56I3PBscRAsYp66E-tL5WDZX8NJMmxZwTut0URvWjK_rRFT27UukPfy-2Y59tqMDHGbjxwcKd_4_a-xnGiqCDHSxVJ-sVD63mnuQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>916853059</pqid></control><display><type>article</type><title>Relation of Adiponectin to Glucose Tolerance Status, Adiposity, and Cardiovascular Risk Factor Load</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Boaz, M. ; Gavish, D. ; Matas, Z. ; Shargorodsky, M. ; Wolfson, N.</creator><contributor>Khunti, K.</contributor><creatorcontrib>Boaz, M. ; Gavish, D. ; Matas, Z. ; Shargorodsky, M. ; Wolfson, N. ; Khunti, K.</creatorcontrib><description>Objective. Adiponectin has anti-atherogenic and anti-inflammatory properties. We investigated the influence of adiponectin on glucose tolerance status, adiposity and cardiovascular risk factors (CVRFs). Design and Patients. Study consisted of 107 subjects: 55 with normal glucose tolerance (NGT) and 52 with impaired glucose regulation (IGR) who were divided into two groups: 24 subjects with impaired fasting glucose (IFG Group) and 28 patients with type 2 diabetes mellitus (DM Group). In additional analysis, study participants were divided into two groups, according to CVRFs: low and high risk. Measurements: Patients were evaluated for glucose, HbA1C, insulin, lipids, CRP, HOMA-IR and adiponectin. Measurements. Patients were evaluated for glucose, HbA1C, insulin, lipids, CRP, HOMA-IR and adiponectin. Results. Adiponectin was significantly higher in NGT group than in IFG (P=0.003) and DM (P=0.01) groups. Adiponectin was significantly, positively associated with HDL and inversely associated with glucose, HbA1c, ALT, AST, TG, HOMA-IR. Patients with higher CVRFs load have lesser adiponectin compared to patients with low cardiovascular risk P<0.0001). Adiponectin was inversely associated with the number of risk factors (r=−0.430, P=0.0001). Conclusions. Circulating adiponectin was significantly lower in subjects with different degree of IGR compared to subjects with normal glucose homeostasis. Adiponectin was significantly lower in high risk group than low risk group and decreased concurrently with increased number of CVRFs.</description><identifier>ISSN: 1687-5214</identifier><identifier>EISSN: 1687-5303</identifier><identifier>DOI: 10.1155/2012/250621</identifier><identifier>PMID: 22253614</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Puplishing Corporation</publisher><subject>Adiponectin - blood ; Adiposity ; Aged ; Biomarkers - blood ; Blood Glucose - analysis ; C-Reactive Protein - analysis ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - physiopathology ; Case-Control Studies ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - physiopathology ; Down-Regulation ; Female ; Glucose Intolerance - blood ; Glucose Intolerance - complications ; Glucose Intolerance - physiopathology ; Glycated Hemoglobin A - analysis ; Humans ; Insulin - blood ; Israel ; Lipids - blood ; Male ; Middle Aged ; Risk Assessment ; Risk Factors</subject><ispartof>Experimental diabetes research, 2012-01, Vol.2012 (2012), p.1-5</ispartof><rights>Copyright © 2012 N. Wolfson et al.</rights><rights>Copyright © 2012 N. Wolfson et al. 2012</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-3fb510c13994528f388427a4927fdde5bd7984e8dec56dae7fa0e15f821b51833</citedby><cites>FETCH-LOGICAL-c437t-3fb510c13994528f388427a4927fdde5bd7984e8dec56dae7fa0e15f821b51833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255106/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255106/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22253614$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Khunti, K.</contributor><creatorcontrib>Boaz, M.</creatorcontrib><creatorcontrib>Gavish, D.</creatorcontrib><creatorcontrib>Matas, Z.</creatorcontrib><creatorcontrib>Shargorodsky, M.</creatorcontrib><creatorcontrib>Wolfson, N.</creatorcontrib><title>Relation of Adiponectin to Glucose Tolerance Status, Adiposity, and Cardiovascular Risk Factor Load</title><title>Experimental diabetes research</title><addtitle>Exp Diabetes Res</addtitle><description>Objective. Adiponectin has anti-atherogenic and anti-inflammatory properties. We investigated the influence of adiponectin on glucose tolerance status, adiposity and cardiovascular risk factors (CVRFs). Design and Patients. Study consisted of 107 subjects: 55 with normal glucose tolerance (NGT) and 52 with impaired glucose regulation (IGR) who were divided into two groups: 24 subjects with impaired fasting glucose (IFG Group) and 28 patients with type 2 diabetes mellitus (DM Group). In additional analysis, study participants were divided into two groups, according to CVRFs: low and high risk. Measurements: Patients were evaluated for glucose, HbA1C, insulin, lipids, CRP, HOMA-IR and adiponectin. Measurements. Patients were evaluated for glucose, HbA1C, insulin, lipids, CRP, HOMA-IR and adiponectin. Results. Adiponectin was significantly higher in NGT group than in IFG (P=0.003) and DM (P=0.01) groups. Adiponectin was significantly, positively associated with HDL and inversely associated with glucose, HbA1c, ALT, AST, TG, HOMA-IR. Patients with higher CVRFs load have lesser adiponectin compared to patients with low cardiovascular risk P<0.0001). Adiponectin was inversely associated with the number of risk factors (r=−0.430, P=0.0001). Conclusions. Circulating adiponectin was significantly lower in subjects with different degree of IGR compared to subjects with normal glucose homeostasis. Adiponectin was significantly lower in high risk group than low risk group and decreased concurrently with increased number of CVRFs.</description><subject>Adiponectin - blood</subject><subject>Adiposity</subject><subject>Aged</subject><subject>Biomarkers - blood</subject><subject>Blood Glucose - analysis</subject><subject>C-Reactive Protein - analysis</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cardiovascular Diseases - physiopathology</subject><subject>Case-Control Studies</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Down-Regulation</subject><subject>Female</subject><subject>Glucose Intolerance - blood</subject><subject>Glucose Intolerance - complications</subject><subject>Glucose Intolerance - physiopathology</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Humans</subject><subject>Insulin - blood</subject><subject>Israel</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><issn>1687-5214</issn><issn>1687-5303</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><recordid>eNqFkctPVTEQxk-MRhBcudZ0R6Jc6fM8NibkBtDkJiaA62ZuO5Xque217YHw31Ny4EZXrmaS-c03j69p3jH6mTGlTjhl_IQr2nL2otlnbd8tlKDi5XPOmdxr3uT8i1LZKtW_bvY450q0TO435hJHKD4GEh05tX4bA5riAymRXIyTiRnJdRwxQTBIrgqUKR_PYPbl_phAsGQJyfp4C9lMIyRy6fNvcg6mxERWEexh88rBmPHtUzxofpyfXS-_LlbfL74tT1cLI0VXFsKtFaOGiWGQivdO9L3kHciBd85aVGvbDb3E3qJRrQXsHFBkyvWc1cZeiIPmy6y7ndYbtAZDSTDqbfIbSPc6gtf_VoK_0T_jrRZc1cltFTh6Ekjxz4S56I3PBscRAsYp66E-tL5WDZX8NJMmxZwTut0URvWjK_rRFT27UukPfy-2Y59tqMDHGbjxwcKd_4_a-xnGiqCDHSxVJ-sVD63mnuQ</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Boaz, M.</creator><creator>Gavish, D.</creator><creator>Matas, Z.</creator><creator>Shargorodsky, M.</creator><creator>Wolfson, N.</creator><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120101</creationdate><title>Relation of Adiponectin to Glucose Tolerance Status, Adiposity, and Cardiovascular Risk Factor Load</title><author>Boaz, M. ; Gavish, D. ; Matas, Z. ; Shargorodsky, M. ; Wolfson, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-3fb510c13994528f388427a4927fdde5bd7984e8dec56dae7fa0e15f821b51833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adiponectin - blood</topic><topic>Adiposity</topic><topic>Aged</topic><topic>Biomarkers - blood</topic><topic>Blood Glucose - analysis</topic><topic>C-Reactive Protein - analysis</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cardiovascular Diseases - physiopathology</topic><topic>Case-Control Studies</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Down-Regulation</topic><topic>Female</topic><topic>Glucose Intolerance - blood</topic><topic>Glucose Intolerance - complications</topic><topic>Glucose Intolerance - physiopathology</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Humans</topic><topic>Insulin - blood</topic><topic>Israel</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><toplevel>online_resources</toplevel><creatorcontrib>Boaz, M.</creatorcontrib><creatorcontrib>Gavish, D.</creatorcontrib><creatorcontrib>Matas, Z.</creatorcontrib><creatorcontrib>Shargorodsky, M.</creatorcontrib><creatorcontrib>Wolfson, N.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental diabetes research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boaz, M.</au><au>Gavish, D.</au><au>Matas, Z.</au><au>Shargorodsky, M.</au><au>Wolfson, N.</au><au>Khunti, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relation of Adiponectin to Glucose Tolerance Status, Adiposity, and Cardiovascular Risk Factor Load</atitle><jtitle>Experimental diabetes research</jtitle><addtitle>Exp Diabetes Res</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>2012</volume><issue>2012</issue><spage>1</spage><epage>5</epage><pages>1-5</pages><issn>1687-5214</issn><eissn>1687-5303</eissn><abstract>Objective. Adiponectin has anti-atherogenic and anti-inflammatory properties. We investigated the influence of adiponectin on glucose tolerance status, adiposity and cardiovascular risk factors (CVRFs). Design and Patients. Study consisted of 107 subjects: 55 with normal glucose tolerance (NGT) and 52 with impaired glucose regulation (IGR) who were divided into two groups: 24 subjects with impaired fasting glucose (IFG Group) and 28 patients with type 2 diabetes mellitus (DM Group). In additional analysis, study participants were divided into two groups, according to CVRFs: low and high risk. Measurements: Patients were evaluated for glucose, HbA1C, insulin, lipids, CRP, HOMA-IR and adiponectin. Measurements. Patients were evaluated for glucose, HbA1C, insulin, lipids, CRP, HOMA-IR and adiponectin. Results. Adiponectin was significantly higher in NGT group than in IFG (P=0.003) and DM (P=0.01) groups. Adiponectin was significantly, positively associated with HDL and inversely associated with glucose, HbA1c, ALT, AST, TG, HOMA-IR. Patients with higher CVRFs load have lesser adiponectin compared to patients with low cardiovascular risk P<0.0001). Adiponectin was inversely associated with the number of risk factors (r=−0.430, P=0.0001). Conclusions. Circulating adiponectin was significantly lower in subjects with different degree of IGR compared to subjects with normal glucose homeostasis. Adiponectin was significantly lower in high risk group than low risk group and decreased concurrently with increased number of CVRFs.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Puplishing Corporation</pub><pmid>22253614</pmid><doi>10.1155/2012/250621</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1687-5214 |
| ispartof | Experimental diabetes research, 2012-01, Vol.2012 (2012), p.1-5 |
| issn | 1687-5214 1687-5303 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3255106 |
| source | MEDLINE; PubMed Central Open Access; PubMed Central |
| subjects | Adiponectin - blood Adiposity Aged Biomarkers - blood Blood Glucose - analysis C-Reactive Protein - analysis Cardiovascular Diseases - blood Cardiovascular Diseases - etiology Cardiovascular Diseases - physiopathology Case-Control Studies Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - physiopathology Down-Regulation Female Glucose Intolerance - blood Glucose Intolerance - complications Glucose Intolerance - physiopathology Glycated Hemoglobin A - analysis Humans Insulin - blood Israel Lipids - blood Male Middle Aged Risk Assessment Risk Factors |
| title | Relation of Adiponectin to Glucose Tolerance Status, Adiposity, and Cardiovascular Risk Factor Load |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A34%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relation%20of%20Adiponectin%20to%20Glucose%20Tolerance%20Status,%20Adiposity,%20and%20Cardiovascular%20Risk%20Factor%20Load&rft.jtitle=Experimental%20diabetes%20research&rft.au=Boaz,%20M.&rft.date=2012-01-01&rft.volume=2012&rft.issue=2012&rft.spage=1&rft.epage=5&rft.pages=1-5&rft.issn=1687-5214&rft.eissn=1687-5303&rft_id=info:doi/10.1155/2012/250621&rft_dat=%3Cproquest_pubme%3E916853059%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=916853059&rft_id=info:pmid/22253614&rfr_iscdi=true |